Biotechnology company pioneering messenger RNA therapeutics and vaccines, gained prominence with COVID-19 vaccine development.
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Moderna.
Profile & Fundamentals
Moderna Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Company profile record
Moderna Inc
Common Stock · Healthcare · Biotechnology
Company
- Company / asset
- Moderna Inc
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 325 Binney Street, Cambridge, MA, United States, 02142
Leadership & scale
- Chief executive
- Mr. Stéphane Bancel M.B.A.
- CEO year born
- 1973
- Full-time employees
- 4.7K
- Fiscal year end
- December
- IPO date
- 2018-12-07
Fundamentals snapshot
- Market Cap
- USD 21.7B
- P/E
- --
- Revenue (Q1 26)
- USD 389.0M
- Profit (Q1 26)
- USD -1.3B
- Dividend Yield
- --
- Revenue (FY 25)
- USD 1.9B
- Shares in public float
- 370.1M
- Insider ownership
- 7.31%
Reporting & identifiers
- Symbol
- MRNA.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US60770K1079
- Asset ID
- equity_cdc413d2-1e92-5151-9d6b-1cbb7c013976
Ownership
Shares Outstanding
Latest: 395.0M | Max: 431.0M | Min: 61.0M
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.